Pitavastatin
Pitavastatin (usually as a calcium salt) is a member of the blood cholesterol lowering medication class of statins.
Clinical data | |
---|---|
Trade names | Livalo, Livazo, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a610018 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth (tablets) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 60% |
Protein binding | 96% |
Metabolism | Liver (CYP2C9, minimally) |
Elimination half-life | 11 hours |
Excretion | Faeces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.171.153 |
Chemical and physical data | |
Formula | C25H24FNO4 |
Molar mass | 421.461 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Like other statins, it is an inhibitor of HMG-CoA reductase, the enzyme that catalyses the first step of cholesterol synthesis.
It was patented in 1987 and approved for medical use in 2003. It is available in Japan, South Korea and in India. In the US, it received FDA approval in 2009. Kowa Pharmaceuticals, a subsidiary of Kowa Company, is the owner of the American patent to pitavastatin.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.